Study for evaluating efficacy and safety of TACE with miriplatin in the treatment of patients with hepatocellular carcinoma
Not Applicable
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000003987
- Lead Sponsor
- Tokai University School of Medicine, Department of Internal Medicine, Division of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who have hypersensitiby to iodine or contrast media. 2. Patients who have severe thyroid or heart diseases. 3. Patients who have uncontrolled malignancies other than HCC. 4. Patients who are pregnant or lactating.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to progression
- Secondary Outcome Measures
Name Time Method